Chinese firm LongBio Pharma’s IgE-targeted antibody may become the first anti-IgE biologic for seasonal allergic rhinitis on the China market if approved following positive Phase III results.
Chinese firm LongBio Pharma’s IgE-targeted antibody may become the first anti-IgE biologic for seasonal allergic rhinitis on the China market if approved following positive Phase III results.